Atara Biotherapeutics 的收益超出预期，导致其股价上涨 0.10 美元至 6.90 美元。 Atara Biotherapeutics beat earnings expectations, causing its stock to rise $0.10 to $6.90.

Atara生物治疗超过预期收入,报告每股损失1.19美元,而预期损失为3.82美元,导致库存增加0.10美元,达到6.90美元。 Atara Biotherapeutics exceeded earnings expectations, reporting a loss of $1.19 per share versus the expected $3.82 loss, leading to a $0.10 stock increase to $6.90. 该公司侧重于Epstein-Barr病毒疾病的治疗,市场上限为3 974万美元。 The company, focusing on treatments for Epstein-Barr virus diseases, has a market cap of $39.74 million. 分析员的评级不尽相同,有总体的“机动购买”共识和17.75美元的目标价格。 Analysts' ratings vary, with an overall "Moderate Buy" consensus and a $17.75 target price. 尽管取得了积极成果,但库存量迄今已下降48%,去年下降60%。 Despite positive results, the stock has fallen 48% year-to-date and 60% over the past year.